The master regulator MYC controls cell behavior by regulating the activity of many other genes, some of which can promote cancer. It does so with the help of enhancers (and super-enhancers) that allow MYC to bind and activate other genes. The relationship between MYC and its enhancers is complex, so Dr. Guo is seeing how MYC levels affect enhancers and how enhancer activity affects MYC levels. He has found evidence for a feedback loop that may be responsible for MYC-induced activation of cancer-promoting genes, and he’s continuing to identify and characterize other MYC-associated enhancers. This knowledge may help stimulate efforts to address MYC’s pro-cancer effects through both prevention and treatment.
Whitehead Institute for Biomedical Research | All Cancers, Leukemia, Lymphoma, Multiple Myeloma | 2015 | Richard A. Young, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This September for Blood Cancer Awareness Month, we look at how we’re working toward a future immune to leukemia, lymphoma, and multiple myeloma.
The latest results from a variety of immunotherapy trials will be revealed during the ESMO Virtual Congress 2020 starting September 19.